Trial Profile
A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Fadraciclib (Primary) ; Fadraciclib (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Fallopian tube cancer; Lymphoma; Ovarian cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors Cyclacel Pharmaceuticals
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Apr 2022 Planned End Date changed from 1 Mar 2021 to 1 Oct 2023.
- 22 Apr 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2023.